Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 21
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Chuang, Y.-C. Lin, H.-Y. Chen, P.-Y. Lin, C.-Y. Wang, J.-T. and Chang, S.-C. 2016. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. Clinical Microbiology and Infection,

    Leather, Helen L. and Wingard, John R. 2016. Thomas’ Hematopoietic Cell Transplantation.

    Pérez-García, A. Landecho, M. F. Beunza, J. J. Conde-Estévez, D. Horcajada, J. P. Grau, S. Gea, A. Mauleón, E. Sorli, L. Gómez, J. Terradas, R. Lucena, J. F. Alegre, F. Huerta, A. and Del Pozo, J. L. 2016. Enterococcal bloodstream infection. Design and validation of a mortality prediction rule. International Journal of Clinical Practice, Vol. 70, Issue. 2, p. 147.

    Zhao, Ming Liang, Liang Ji, Liwei Chen, Di Zhang, Yatong Zhu, Yuanchao and Patel, Khilna 2016. Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. International Journal of Antimicrobial Agents, Vol. 48, Issue. 3, p. 231.

    Barber, Katie E King, S Travis Stover, Kayla R and Pogue, Jason M 2015. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Review of Anti-infective Therapy, Vol. 13, Issue. 3, p. 363.

    Britt, Nicholas S. Potter, Emily M. Patel, Nimish and Steed, Molly E. 2015. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clinical Infectious Diseases, Vol. 61, Issue. 6, p. 871.

    Lisboa, Luiz F. Miranda, Bianca G. Vieira, Marjorie B. Dulley, Frederico L. Fonseca, Guilherme G. Guimarães, Thais Levin, Anna S. Shikanai-Yasuda, Maria A. and Costa, Silvia F. 2015. Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant Enterococcus spp. International Journal of Infectious Diseases, Vol. 33, p. 171.

    Qazi, Junaid Casserly, Liam F. O'Connor, Ciara Finnegan, Cathriona Power, Lorraine Dunne, Colum P. and O'Connell, Nuala H. 2015. A case of fatal daptomycin-resistant, vancomycin-resistant enterococcal infective endocarditis in end-stage kidney disease. JMM Case Reports, Vol. 2, Issue. 5,

    Chuang, Yu-Chung Wang, Jann-Tay Lin, Hsin-Yi and Chang, Shan-Chwen 2014. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infectious Diseases, Vol. 14, Issue. 1,

    Munita, Jose M. Murray, Barbara E. and Arias, Cesar A. 2014. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. International Journal of Antimicrobial Agents, Vol. 44, Issue. 5, p. 387.

    Rosa, Regis G. Schwarzbold, Alexandre V. Santos, Rodrigo P. dos Turra, Eduardo E. Machado, Denise P. and Goldani, Luciano Z. 2014. Vancomycin-ResistantEnterococcus faeciumBacteremia in a Tertiary Care Hospital: Epidemiology, Antimicrobial Susceptibility, and Outcome. BioMed Research International, Vol. 2014, p. 1.

    Tavadze, M Rybicki, L Mossad, S Avery, R Yurch, M Pohlman, B Duong, H Dean, R Hill, B Andresen, S Hanna, R Majhail, N Copelan, E Bolwell, B Kalaycio, M and Sobecks, R 2014. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, Vol. 49, Issue. 10, p. 1310.

    Cheah, A.A.Y. Spelman, T. Liew, D. Peel, T. Howden, B.P. Spelman, D. Grayson, M.L. Nation, R.L. and Kong, D.D.M. 2013. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clinical Microbiology and Infection, Vol. 19, Issue. 4, p. E181.

    Cho, Sung-Yeon Lee, Dong-Gun Choi, Su-Mi Kwon, Jae-Cheol Kim, Si-Hyun Choi, Jae-Ki Park, Sun Hee Park, Yeon-Joon Choi, Jung-Hyun and Yoo, Jin-Hong 2013. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infectious Diseases, Vol. 13, Issue. 1,

    McCracken, M. Wong, A. Mitchell, R. Gravel, D. Conly, J. Embil, J. Johnston, L. Matlow, A. Ormiston, D. Simor, A. E. Smith, S. Du, T. Hizon, R. and Mulvey, M. R. 2013. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. Journal of Antimicrobial Chemotherapy, Vol. 68, Issue. 7, p. 1505.

    Reyes, Katherine and Zervos, Marcus 2013. Endocarditis Caused by Resistant Enterococcus: An Overview. Current Infectious Disease Reports, Vol. 15, Issue. 4, p. 320.

    Shukla, Bhavarth S. Gauthier, Timothy P. Correa, Ricardo Smith, Laura and Abbo, Lilian 2013. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. International Journal of Clinical Pharmacy, Vol. 35, Issue. 5, p. 697.

    Llinares, Pedro and Iribarren, José Antonio 2012. Tratamiento con daptomicina en pacientes con bacteriemia. Enfermedades Infecciosas y Microbiología Clínica, Vol. 30, p. 17.

    Lu, C.-L. Chuang, Y.-C. Chang, H.-C. Chen, Y.-C. Wang, J.-T. and Chang, S.-C. 2012. Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis. Journal of Antimicrobial Chemotherapy, Vol. 67, Issue. 9, p. 2243.

    McGregor, Jessina C. Hartung, Daniel M. Allen, George P. Taplitz, Randy A. Traver, Robin Tong, Tony and Bearden, David T. 2012. Risk factors associated with linezolid-nonsusceptible enterococcal infections. American Journal of Infection Control, Vol. 40, Issue. 9, p. 886.


Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents

  • J. A. McKINNELL (a1) (a2), M. PATEL (a3) (a4), R. M. SHIRLEY (a3), D. F. KUNZ (a5), S. A. MOSER (a6) and J. W. BADDLEY (a3) (a4)
  • DOI:
  • Published online: 15 November 2010

Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSI) are a growing problem with few clinical trials to guide therapy. We conducted a retrospective study of management and predictors of mortality for VRE-BSI at a tertiary-care centre from January 2005 to August 2008. Univariate and multivariable analyses examined the relationship of patient characteristics and antibiotic therapy with 30-day all-cause mortality. Rates of VRE-BSI increased from 0·06 to 0·17 infections/1000 patient-days (P=0·03). For 235 patients, 30-day mortality was 34·9%. Patients were primarily treated with linezolid (44·2%) or daptomycin (36·5%). Factors associated with mortality were haemodialysis [odds ratio (OR) 3·2, 95% confidence interval (CI) 1·6–6·3, P=0·007], mechanical ventilation (OR 3·7, 95% CI 1·3–10·4, P=0·01), and malnutrition (OR 2·0, 95% CI 1·0–4·0, P=0·046). Use of linezolid, but not daptomycin (P=0·052) showed a trend towards an association with survival. In conclusion, VRE-BSI is a growing problem, associated with significant 30-day mortality. Multiple factors were associated with poor outcomes at our hospital.

Corresponding author
*Author for correspondence: J. A. McKinnell, M.D., Los Angeles Biomedical Research Institute, Division of Infectious Diseases, 1124 West Carson Street, Torrance, CA 90502, USA. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2.LM Deshpande , Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Diseases 2007; 58: 163170.

3.NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. American Journal of Infection Control 2004; 32: 470485.

4.EN Vergis , Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Annals of Internal Medicine 2001; 135: 484492.

5.KM Erlandson , Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clinical Infectious Diseases 2008; 46: 3036.

6.CA DiazGranados , JA Jernigan . Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. Journal of Infectious Diseases 2005; 191: 588595.

7.M Gearhart , Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clinical Transplantation 2005; 19: 711716.

8.JM Garbutt , Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clinical Infectious Diseases 2000; 30: 466472.

9.JH Song , Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. Journal of Antimicrobial Chemotherapy 2008; 61: 838844.

11.GA Papanicolaou , Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clinical Infectious Diseases 1996; 23: 760766.

12.CA DiazGranados , Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clinical Infectious Diseases 2005; 41: 327333.

13.RE Warren . Daptomycin in endocarditis and bacteraemia: a British perspective. Journal of Antimicrobial Chemotherapy 2008; 62 (Suppl. 3): 2533.

14.BS Schwartz , PD Ngo , BJ Guglielmo . Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Annals of Pharmacotherapy 2008; 42: 289290.

15.JF Mohr , Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). International Journal of Antimicrobial Agents 2009; 33: 543548.

16.V Mave , Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? Journal of Antimicrobial Chemotherapy 2009; 64: 175180.

18.SM Bhavnani , A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagnostic Microbiology and Infectious Diseases 2000; 36: 145158.

19.TC Horan , M Andrus , MA Dudeck . CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control 2008; 36: 309332.

20.ME Charlson , A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40: 373383.

21.HW Boucher , Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 2009; 48: 112.

22.R Reik , The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagnostic Microbiology and Infectious Diseases 2008; 62: 8185.

24.DD Poutsiaka , Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Journal of Infection 2007; 54: 567571.

25.JA Segreti , CW Crank , MS Finney . Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347–332.

26.II Raad , Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrobial Agents and Chemotherapy 2005; 49: 50465050.

27.RC Moellering , The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. Journal of Antimicrobial Chemotherapy 1999; 44: 251261.

28.N Kvirikadze , Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scandinavian Journal of Infectious Diseases 2006; 38: 290292.

29.BA Cunha , N Mickail , L Eisenstein . E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart and Lung 2007; 36: 456461.

30.DP Levine . Clinical experience with daptomycin: bacteraemia and endocarditis. Journal of Antimicrobial Chemotherapy 2008; 62 (Suppl. 3): 3539.

31.JW Chien , ML Kucia , RA Salata . Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical Infectious Diseases 2000; 30: 146151.

32.VG Fowler Jr., Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clinical Infectious Diseases 1998; 27: 478486.

33.M Patel , Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagnostic Microbiology and Infectious Diseases 2005; 52: 2934.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *